Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2001 Sep-Oct;7(5):797–806. doi: 10.3201/eid0705.010505

Cost-effectiveness of a potential vaccine for Coccidioides immitis.

A E Barnato 1, G D Sanders 1, D K Owens 1
PMCID: PMC2631863  PMID: 11747691

Abstract

Coccidioidomycosis, a systemic fungal infection, affects Americans living in the Southwest. We evaluated the cost- effectiveness of a potential vaccine against Coccidioides immitis. Using a decision model we developed, we estimate that among children, vaccination would saved 1.9 quality-adjusted life days (QALD) and $33 per person. Among adults, screening followed by vaccination would save 0.5 QALD per person and cost $62,000 per quality adjusted life year gained over no vaccination. If the birth cohort in highly endemic counties of California and Arizona were immunized in 2001, 11 deaths would be averted and $3 million would be saved (in net present value) over the lifetime of these infants. Vaccination of adults to prevent disseminated coccidioidomycosis would provide a modest health benefit similar in magnitude to other vaccines but would increase net expenditures. Vaccination of children in highly endemic regions would provide a larger health benefit and would reduce total health care expenditures.

Full Text

The Full Text of this article is available as a PDF (127.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arsura E. L. The association of age and mortality in coccidioidomycosis. J Am Geriatr Soc. 1997 Apr;45(4):532–533. doi: 10.1111/j.1532-5415.1997.tb05189.x. [DOI] [PubMed] [Google Scholar]
  2. Arsura E. L. The association of age and mortality in coccidioidomycosis. J Am Geriatr Soc. 1997 Apr;45(4):532–533. doi: 10.1111/j.1532-5415.1997.tb05189.x. [DOI] [PubMed] [Google Scholar]
  3. Assad S., Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine. 1999 Aug 20;18(1-2):57–67. doi: 10.1016/s0264-410x(99)00179-6. [DOI] [PubMed] [Google Scholar]
  4. Assad S., Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine. 1999 Aug 20;18(1-2):57–67. doi: 10.1016/s0264-410x(99)00179-6. [DOI] [PubMed] [Google Scholar]
  5. Bayer A. S. Fungal pneumonias: pulmonary coccidioidal syndromes (Part 2). Miliary, nodular, and cavitary pulmonary coccidioidomycosis; chemotherapeutic and surgical considerations. Chest. 1981 Jun;79(6):686–691. doi: 10.1378/chest.79.6.686. [DOI] [PubMed] [Google Scholar]
  6. Bayer A. S. Fungal pneumonias; pulmonary coccidioidal syndromes (Part I). Primary and progressive primary coccidioidal pneumonias -- diagnostic, therapeutic, and prognostic considerations. Chest. 1981 May;79(5):575–583. doi: 10.1378/chest.79.5.575. [DOI] [PubMed] [Google Scholar]
  7. Beck J. R., Pauker S. G. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419–458. doi: 10.1177/0272989X8300300403. [DOI] [PubMed] [Google Scholar]
  8. Bouza E., Dreyer J. S., Hewitt W. L., Meyer R. D. Coccidioidal meningitis. An analysis of thirty-one cases and review of the literature. Medicine (Baltimore) 1981 May;60(3):139–172. [PubMed] [Google Scholar]
  9. Catanzaro A. Coccidioidin sensitivity in San Diego schools. Sabouraudia. 1979 Jun;17(2):85–89. doi: 10.1080/00362177985380131. [DOI] [PubMed] [Google Scholar]
  10. Catanzaro A., Galgiani J. N., Levine B. E., Sharkey-Mathis P. K., Fierer J., Stevens D. A., Chapman S. W., Cloud G. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med. 1995 Mar;98(3):249–256. doi: 10.1016/s0002-9343(99)80371-4. [DOI] [PubMed] [Google Scholar]
  11. Centers for Disease Control and Prevention (CDC) Coccidioidomycosis--Arizona, 1990-1995. MMWR Morb Mortal Wkly Rep. 1996 Dec 13;45(49):1069–1073. [PubMed] [Google Scholar]
  12. Centers for Disease Control and Prevention (CDC) Update: coccidioidomycosis--California, 1991-1993. MMWR Morb Mortal Wkly Rep. 1994 Jun 17;43(23):421–423. [PubMed] [Google Scholar]
  13. Dodge R. R., Lebowitz M. D., Barbee R., Burrows B. Estimates of C. immitis infection by skin test reactivity in an endemic community. Am J Public Health. 1985 Aug;75(8):863–865. doi: 10.2105/ajph.75.8.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dodge R. R., Lebowitz M. D., Barbee R., Burrows B. Estimates of C. immitis infection by skin test reactivity in an endemic community. Am J Public Health. 1985 Aug;75(8):863–865. doi: 10.2105/ajph.75.8.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Doto I. L., Tosh F. E., Farnsworth S. F., Furcolow M. L. Coccidioidin, histoplasmin, and tuberculin sensitivity among school children in Maricopa County, Arizona. Am J Epidemiol. 1972 May;95(5):464–474. doi: 10.1093/oxfordjournals.aje.a121413. [DOI] [PubMed] [Google Scholar]
  16. EDWARDS P. Q., PALMER C. E. Prevalence of sensitivity to coccidioidin, with special reference to specific and nonspecific reactions to coccidioidin and to histoplasmin. Dis Chest. 1957 Jan;31(1):35–60. doi: 10.1378/chest.31.1.35. [DOI] [PubMed] [Google Scholar]
  17. Einstein H. E., Johnson R. H. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis. 1993 Mar;16(3):349–354. doi: 10.1093/clind/16.3.349. [DOI] [PubMed] [Google Scholar]
  18. Einstein H. E., Johnson R. H. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis. 1993 Mar;16(3):349–354. doi: 10.1093/clind/16.3.349. [DOI] [PubMed] [Google Scholar]
  19. Flynn N. M., Hoeprich P. D., Kawachi M. M., Lee K. K., Lawrence R. M., Goldstein E., Jordan G. W., Kundargi R. S., Wong G. A. An unusual outbreak of windborne coccidioidomycosis. N Engl J Med. 1979 Aug 16;301(7):358–361. doi: 10.1056/NEJM197908163010705. [DOI] [PubMed] [Google Scholar]
  20. Fredrich B. E. A skin test survey of valley fever in Tijuana, Mexico. Soc Sci Med. 1989;29(10):1217–1227. doi: 10.1016/0277-9536(89)90365-1. [DOI] [PubMed] [Google Scholar]
  21. Gage B. F., Cardinalli A. B., Owens D. K. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996 Sep 9;156(16):1829–1836. [PubMed] [Google Scholar]
  22. Galgiani J. N., Catanzaro A., Cloud G. A., Higgs J., Friedman B. A., Larsen R. A., Graybill J. R. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med. 1993 Jul 1;119(1):28–35. doi: 10.7326/0003-4819-119-1-199307010-00005. [DOI] [PubMed] [Google Scholar]
  23. Galgiani J. N., Catanzaro A., Cloud G. A., Johnson R. H., Williams P. L., Mirels L. F., Nassar F., Lutz J. E., Stevens D. A., Sharkey P. K. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000 Nov 7;133(9):676–686. doi: 10.7326/0003-4819-133-9-200011070-00009. [DOI] [PubMed] [Google Scholar]
  24. Galgiani J. N. Coccidioidomycosis. Curr Clin Top Infect Dis. 1997;17:188–204. [PubMed] [Google Scholar]
  25. Galgiani J. N. Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. Ann Intern Med. 1999 Feb 16;130(4 Pt 1):293–300. doi: 10.7326/0003-4819-130-4-199902160-00015. [DOI] [PubMed] [Google Scholar]
  26. Geller R. D., Maynard J. E., Jones V. Coccidioidin sensitivity among Southwestern American Indians. Am Rev Respir Dis. 1973 Feb;107(2):301–302. doi: 10.1164/arrd.1973.107.2.301. [DOI] [PubMed] [Google Scholar]
  27. Gold M. R., Franks P., McCoy K. I., Fryback D. G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998 Jun;36(6):778–792. doi: 10.1097/00005650-199806000-00002. [DOI] [PubMed] [Google Scholar]
  28. Gold M. R., Franks P., McCoy K. I., Fryback D. G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998 Jun;36(6):778–792. doi: 10.1097/00005650-199806000-00002. [DOI] [PubMed] [Google Scholar]
  29. Graybill J. R., Stevens D. A., Galgiani J. N., Dismukes W. E., Cloud G. A. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med. 1990 Sep;89(3):282–290. doi: 10.1016/0002-9343(90)90339-f. [DOI] [PubMed] [Google Scholar]
  30. Hooper R., Poppell G., Curley R., Husted S., Schillaci R. Coccidioidomycosis among military personnel in Southern California. Mil Med. 1980 Sep;145(9):620–623. [PubMed] [Google Scholar]
  31. Johnson W. M. Occupational factors in coccidioidomycosis. J Occup Med. 1981 May;23(5):367–374. [PubMed] [Google Scholar]
  32. Kirkland T. N., Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis. 1996 Jul-Sep;2(3):192–199. doi: 10.3201/eid0203.960305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lang J., Wood S. C. Development of orphan vaccines: an industry perspective. Emerg Infect Dis. 1999 Nov-Dec;5(6):749–756. doi: 10.3201/eid0506.990602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Larwood T. R. Coccidioidin skin testing in Kern County, California: decrease in infection rate over 58 years. Clin Infect Dis. 2000 Mar;30(3):612–613. doi: 10.1086/313724. [DOI] [PubMed] [Google Scholar]
  35. Levine H. B., Gonzalez-Ochoa A., Ten Eyck D. R. Dermal sensitivity to Coccidioides immitis. A comparison of responses elicited in man by spherulin and coccidioidin. Am Rev Respir Dis. 1973 Mar;107(3):379–386. doi: 10.1164/arrd.1973.107.3.379. [DOI] [PubMed] [Google Scholar]
  36. Levine H. B., Gonzalez-Ochoa A., Ten Eyck D. R. Dermal sensitivity to Coccidioides immitis. A comparison of responses elicited in man by spherulin and coccidioidin. Am Rev Respir Dis. 1973 Mar;107(3):379–386. doi: 10.1164/arrd.1973.107.3.379. [DOI] [PubMed] [Google Scholar]
  37. Levine H. B., Restrepon A., Eyck D. R., Stevens D. A. Spherulin and coccidioidin: cross-reactions in dermal sensitivity to histoplasmin and paracoccidioidin. Am J Epidemiol. 1975 Jun;101(6):512–516. doi: 10.1093/oxfordjournals.aje.a112122. [DOI] [PubMed] [Google Scholar]
  38. Levine H. B., Restrepon A., Eyck D. R., Stevens D. A. Spherulin and coccidioidin: cross-reactions in dermal sensitivity to histoplasmin and paracoccidioidin. Am J Epidemiol. 1975 Jun;101(6):512–516. doi: 10.1093/oxfordjournals.aje.a112122. [DOI] [PubMed] [Google Scholar]
  39. MADDY K. T. The geographic distribution of coccidioides immitis and possible ecologic implications. Ariz Med. 1958 Mar;15(3):178–188. [PubMed] [Google Scholar]
  40. MADDY K. T. The geographic distribution of coccidioides immitis and possible ecologic implications. Ariz Med. 1958 Mar;15(3):178–188. [PubMed] [Google Scholar]
  41. Niu M. T., Rhodes P., Salive M., Lively T., Davis D. M., Black S., Shinefield H., Chen R. T., Ellenberg S. S. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol. 1998 Jun;51(6):503–510. doi: 10.1016/s0895-4356(98)00014-6. [DOI] [PubMed] [Google Scholar]
  42. Oldfield E. C., 3rd, Bone W. D., Martin C. R., Gray G. C., Olson P., Schillaci R. F. Prediction of relapse after treatment of coccidioidomycosis. Clin Infect Dis. 1997 Nov;25(5):1205–1210. doi: 10.1086/516115. [DOI] [PubMed] [Google Scholar]
  43. Pappagianis D. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis. 1993 Sep;148(3):656–660. doi: 10.1164/ajrccm/148.3.656. [DOI] [PubMed] [Google Scholar]
  44. Pérez J. A., Jr, Johnson R. H., Caldwell J. W., Arsura E. L., Nemecheck P. Fluconazole therapy in coccidioidal meningitis maintained with intrathecal amphotericin B. Arch Intern Med. 1995 Aug 7;155(15):1665–1668. doi: 10.1001/archinte.1995.00430150157016. [DOI] [PubMed] [Google Scholar]
  45. Sarosi G. A., Parker J. D., Doto I. L., Tosh F. E. Chronic pulmonary coccidioidomycosis. N Engl J Med. 1970 Aug 13;283(7):325–329. doi: 10.1056/NEJM197008132830701. [DOI] [PubMed] [Google Scholar]
  46. Schneider E., Hajjeh R. A., Spiegel R. A., Jibson R. W., Harp E. L., Marshall G. A., Gunn R. A., McNeil M. M., Pinner R. W., Baron R. C. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA. 1997 Mar 19;277(11):904–908. [PubMed] [Google Scholar]
  47. Sisk J. E., Moskowitz A. J., Whang W., Lin J. D., Fedson D. S., McBean A. M., Plouffe J. F., Cetron M. S., Butler J. C. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 1997 Oct 22;278(16):1333–1339. [PubMed] [Google Scholar]
  48. Sonnenberg F. A., Beck J. R. Markov models in medical decision making: a practical guide. Med Decis Making. 1993 Oct-Dec;13(4):322–338. doi: 10.1177/0272989X9301300409. [DOI] [PubMed] [Google Scholar]
  49. Standaert S. M., Schaffner W., Galgiani J. N., Pinner R. W., Kaufman L., Durry E., Hutcheson R. H. Coccidioidomycosis among visitors to a Coccidioides immitis-endemic area: an outbreak in a military reserve unit. J Infect Dis. 1995 Jun;171(6):1672–1675. doi: 10.1093/infdis/171.6.1672. [DOI] [PubMed] [Google Scholar]
  50. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  51. Tucker R. M., Denning D. W., Dupont B., Stevens D. A. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990 Jan 15;112(2):108–112. doi: 10.7326/0003-4819-112-2-108. [DOI] [PubMed] [Google Scholar]
  52. Vincent T., Galgiani J. N., Huppert M., Salkin D. The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis. 1993 Feb;16(2):247–254. doi: 10.1093/clind/16.2.247. [DOI] [PubMed] [Google Scholar]
  53. Werner S. B., Pappagianis D., Heindl I., Mickel A. An epidemic of coccidioidomycosis among archeology students in northern California. N Engl J Med. 1972 Mar 9;286(10):507–512. doi: 10.1056/NEJM197203092861003. [DOI] [PubMed] [Google Scholar]
  54. Wright J. C., Weinstein M. C. Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med. 1998 Aug 6;339(6):380–386. doi: 10.1056/NEJM199808063390606. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES